AlphaPrime integrates its AuroraPrime platform with OpenAI, enhancing clinical research with ChatGPT and exploring AGI applications in drug development.
On October 12, 2022, AlphaPrime Life Sciences completed A+ round financing of tens of millions, led by Han Kang Capital and advised by Huaxing Capital.